Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus

논문상세정보
' Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • hepacivirus
  • interleukin-28b
  • pegylatedinterferon
  • ribavirin
  • simeprevir
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
49 0

0.0%